Opus Genetics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://opusgtx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Not Applicable
Recruiting
- Conditions
- ARBBVMDAutosomal-Dominant BestrophinopathyBest Vitelliform Macular Dystrophy
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Opus Genetics, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT07185256
- Locations
- 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Opus Genetics, Inc
- Target Recruit Count
- 15
- Registration Number
- NCT05616793
- Locations
- 🇺🇸
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
News
No news found